Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 25 more
Nothing from your lists
KALA BIO, Inc. · “On September 9, 2026, the Board of Directors of KALA BIO, Inc. (the “Company”) established November 3, 2026 as the date of the Company’s next annual meeting of stockholders (the “Annual Meeting”).”¶1
SDR Drone, Inc. · “The Company subsequently restated its financial statements as of and for the years ended December 31, 2025 and 2024.”¶1
Selectis Health, Inc. · “As a result of the acceptance for payment of the Shares pursuant to the Offer, a change in control of the Company occurred at the Acceptance Time.”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
Fiscal 2026 highlights included revenue of $21.4 B, operating income of $5.9 B, net income of $4.6 B, diluted net income per share of $16.46, and cash flow from operations of $8.8 B.¶2¶3¶4¶5
In May 2026, Intuit initiated a reorganization plan that included reducing its full-time workforce and closing certain sites, recording a $293 million charge during fiscal 2026.¶6
In June 2026, Intuit issued $1.75 billion of senior unsecured notes and used the net proceeds and cash on hand in August 2026 to repay $750 million of notes due in September 2026.¶7¶8¶9
At July 31, 2026, Intuit had authorization for up to $7.9 billion in stock repurchases and had declared fiscal 2026 cash dividends totaling $4.80 per share, or approximately $1.3 billion.
What changed since last yearRisk factors: 427 sentences against 423 last year · 86 new · 82 gone
new“A security incident involving third parties we rely on may have serious negative consequences for our businesses, including disclosure of sensitive customer or workforce information, or confidential or competitively sensitive information regarding our business, including intellectual property and other proprietary data; make our products more vulnerable to fraudulent activity; cause temporary or sustained unavailability of our software and systems; result in possible litigation, fines, penalties and damages; result in loss of customer confidence; cause material harm to our reputation and brands; lead to further regulation and oversight by federal or state agencies; result in an adverse financial condition; and result in a reduced stock price.”¶13
new“Our technologies, systems, and networks have been subject to, and are increasingly likely to continue to be the target of, cyberattacks, computer viruses, ransomware or other malware, worms, social engineering, malicious software programs, insider threats, denial-of-service attacks and other cybersecurity threats that have in the past, and could in the future, result in the unauthorized release, gathering, monitoring, use, loss or destruction of sensitive and personal information of our customers and our workforce, or Intuit's sensitive business data or cause temporary or sustained unavailability of our data, software, and systems.”¶14
revised“However, the platform owners have wide discretion to change the pricing structure, terms of service and other policies or practices that can affect the visibility or the availability of our offerings.”¶15
was“However, the platform owners have wide discretion to change the pricing structure, terms of service and other policies with respect to us and other developers.”¶16
revised“Our failure to fulfill the requirements of the FTC’s order could result in fines, enforcement action, and reputational harm.”¶17
was“Our failure to fulfill the requirements of the FTC’s order could result in fines, penalties, enforcement inquiries, investigations and claims, and negatively impact our business and reputation.”¶18
On September 9, 2026, KALA BIO’s Board of Directors established November 3, 2026 as the date of its next annual meeting of stockholders.¶1
Rule 14a-8 proposals must be received by the Company’s Secretary at its principal executive offices by September 19, 2026 for inclusion in the proxy materials.¶2
Stockholders nominating a director or proposing matters under the By-Laws must submit notice to the Company’s Secretary by September 19, 2026.¶3
The Company determined that its previously issued 2025 and 2024 financial statements, related audit reports, and specified interim financial statements should no longer be relied upon after material misstatements were identified.¶2¶3¶4¶5
The Company filed Amendment No. 1 to Form 10-K/A on May 28, 2026, containing restated financial statements for the years ended December 31, 2025 and 2024 and a dual-dated auditor’s report.¶1
Corrections increased 2025 net loss by $1,569,224 and increased accumulated deficit at December 31, 2025, from $3,745,941 as previously reported to $5,315,165 as restated.¶6
Corrections increased 2024 net loss by $826,206, increased accumulated deficit from $3,096,015 as previously reported to $3,922,221 as restated, and produced restated basic and diluted net loss per share of $(0.56).¶7
The Offer expired on August 31, 2026, and Merger Sub accepted 2,789,027 Shares tendered at $5.75 per Share, representing approximately 90.93% of outstanding Shares.¶2¶3¶4
Upon completion of the Merger, each remaining Share will convert into the right to receive $5.75 in cash, and the Company will become an indirect wholly owned subsidiary of Parent.¶5¶6¶7
The Lenders provided $18,226,250.00 of term loans bearing interest at 5.0% per annum and maturing on August 28, 2031.¶8¶9¶10
Upon completion of the Merger, stockholders will cease to have stockholder rights, while Lance J. Baller resigned as a director and Abraham Schwartz and Zalman Schapiro became directors.¶11¶12¶13¶14
On September 9, 2026, the entire issued and to be issued share capital of Barinthus Biotherapeutics plc was acquired by Topco, making the Company a wholly-owned subsidiary of Topco.¶2¶3
Topco acquired all Company Shares in exchange for 0.111 shares of Topco common stock for each Company Share in issue, with each Company ADS representing one Company Share.¶4
The Deposit Agreement among the Company, The Bank of New York Mellon and the owners and holders of Company ADSs was terminated when the Scheme of Arrangement became effective.¶5
Following the Scheme’s effectiveness, no Company ADSs were issued or outstanding, no public trading market remained, and shareholders retained only rights to receive consideration under the Scheme of Arrangement.¶6¶7
On September 2, 2026, the Audit Committee approved BDO USA, P.C.’s dismissal, effective after BDO completes its audit for the fiscal year ending September 27, 2026, and the Company files its Annual Report on Form 10-K.¶1
The Audit Committee approved Grant Thornton as the Company’s independent registered public accounting firm for the fiscal year ending September 26, 2027, subject to customary client acceptance procedures and effective after BDO’s fiscal 2026 audit and Form 10-K filing.¶2
BDO’s reports for the fiscal years ended September 28, 2025 and September 29, 2024 had no adverse or disclaimer opinions, and the material weakness remediated as of September 29, 2024 was the only reportable event.¶3¶4
On September 8, 2026, Xylem entered into a senior unsecured revolving credit facility with an aggregate principal amount of up to $1,500,000,000 for working capital and other general corporate purposes.¶1
The 2026 Credit Agreement permits increases of up to $500,000,000 for a maximum aggregate principal amount of $2,000,000,000, and no borrowings were outstanding on September 8, 2026.¶1¶2
In connection with entering into the 2026 Credit Agreement, Xylem terminated its 2023 Credit Agreement, which provided a senior unsecured $1,000,000,000 revolving credit facility with increases of up to $300,000,000 for a maximum aggregate principal amount of $1,300,000,000.¶3
The PNC Credit Agreement matures on September 9, 2031 and replaces the Company's existing credit facility with Wheaton Bank & Trust Company, N.A.¶1
The PNC Credit Facility provides aggregate commitments of up to $300.0 million, including a $200.0 million revolving facility, a $50.0 million term loan and a $50.0 million delayed draw term loan.¶2
The Company terminated the Wintrust Credit Agreement, incurred no early termination penalties, prepayment fees or other material fees, and repaid approximately $118.1 million of principal indebtedness using PNC Credit Facility proceeds.¶3
Existing Letters of Credit totaling approximately $7.0 million will remain outstanding until expiration, with the latest expiring by its terms in April 2027.¶4
The 2026 Term Loan will mature on September 1, 2033, carries a seven-year term with 25-year amortization, and has a balloon payment of outstanding principal due on September 1, 2033.¶1
On September 8, 2026, Wild Animal – Georgia entered into a Rate Conversion Agreement that converts the variable interest payments into a fixed rate obligation of 7.35% over the loan term.¶2
On September 9, 2026, CenterPoint Energy and its wholly owned subsidiaries replaced their existing revolving credit facilities with four facilities totaling $4.6 billion in aggregate commitments, without termination penalties.¶1
CenterPoint replaced its existing $2.4 billion unsecured revolving credit facility with a new $2.2 billion five-year senior unsecured revolving credit facility.¶2
Houston Electric, CERC and SIGECO replaced existing facilities of $300 million, $1.05 billion and $250 million with new five-year facilities of $1.0 billion, $1.1 billion and $300 million, respectively.¶3¶4¶5
On September 8, 2026, the Company processed eight redemption requests, redeeming 8,200 shares of Series D Preferred Stock at approximately $41.66 per share and settling the aggregate price with 348,896 shares of Common Stock.¶1¶2¶3
The Notes’ conversion price was further adjusted to approximately $0.54 per share of Common Stock, or approximately 46.43 shares per $25.00 of principal amount, representing a 45% discount to $0.98.¶4
To date, the Company has processed 442 redemption requests covering 1,827,228 shares of Series D Preferred Stock and issued approximately 473,000 shares of Common Stock in settlement.¶5¶6
As of September 8, 2026, the Company had 4,924,701 shares of Common Stock and 1,726,704 shares of Series D Preferred Stock outstanding.¶7
On September 8, 2026, the Company filed a Certificate of Validation with Delaware’s Secretary of State to give effect to the Reverse Stock Split, effective as of May 4, 2026 at 12:01 a.m. Eastern Time.¶2¶3
Stockholders approved the 1-for-37 reverse stock split and the corresponding Certificate of Validation.¶4¶1
Stockholders approved changing the Company’s name from Twin Vee PowerCats Co. to Twin Vee Bahama Co.¶5¶6
Stockholders approved the proposed adjournment to solicit additional proxies if needed.¶7¶8
